Biogen Idec Launches MS Drug Tysabri, Avonex Pen In Japan
This article was originally published in PharmAsia News
Executive Summary
Biogen Idec Japan has launched the humanized monoclonal antibody Tysabri 300 mg (natalizumab) infusion for multiple sclerosis treatment and the interferon beta agent Avonex (interferon beta-1a) Pen on June 4, the company announced on the same day.
You may also be interested in...
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.